A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients

AIDS

Volumn 10, Issue 6, 1996, Pages 635-641

  Carr, Andrew ^a   Vella, Stefano ^b   De Jong, Menno D ^c   Sorice, Franco ^d   Imrie, Allison ^a   Boucher, Charles A ^c   Cooper, David A ^a,e  

^a ST VINCENT S HOSPITAL   (Australia)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

HIV; Nevirapine; Non nucleoside reverse transcriptase inhibitor; Zidovudine

Indexed keywords

ANTIGEN P24; ANTIVIRUS AGENT; BETA 2 MICROGLOBULIN; CD4 ANTIGEN; NEVIRAPINE; ZIDOVUDINE;

ADULT; ANTIGEN ANTIBODY COMPLEX; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH;

EID: 0029896976     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199606000-00009     Document Type: Article

References (26)

1. Fischl MA, Richman DD, Hansen N, et al.: The efficacy and safety of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus (HIV) infection: a double-blind, placebo-controlled trial. Ann Intern Med 1990, 112:727-737.
2. Volberding PA, Lagakos SW, Koch NA, et al.: Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled clinical trial in persons with less than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990, 332:941-944.
3. Seligmann M, Warell DA, Aboulker J-P, et al.: Concorde: a randomised, double-blind, controlled trial comparing immediate and deferred zidovudine in asymptomatic HIV infection. Lancet 1994, 343:871-881.
4. Cooper DA, Gattel JM, Kroon S, et al.: Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N Engl J Med 1993, 329:297-303.
5. Kahn JO, Lagakos SW, Richman DD, et al.: A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992, 327:581-587.
6. Schooley R, and the Wellcome Resistance Study Collaborative Group: Trial of ZDV/DDI vs ZDV/DDC vs ZDV alone in HIV-infected patients with CD4+ cell counts less than 300; preliminary results. 4th European Conference on Clinical Aspects and Treatment of HIV Infection. Milan, March, 1994, [abstract 052].
7. Meng T-C, Fischl MA, Boota AM, et al.: Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. Ann Intern Med 1992, 116:13-20.
8. Fischl MA, Stanley K, Collier AC, et al.: Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995, 122:24-32.
9. 3. 2nd National Conference on Human Retroviruses and Related Infections. Washington, DC, January 1995 [abstract LB35].
10. 3. 2nd National Conference on Human Retroviruses and Related Infections. Washington DC, January 1995 [abstract LB32].
11. Merluzzi VJ, Margrave KD, Labadia M, et al.: Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990, 250:1411-1413.
12. Koup RA, Merluzzi VJ, Hargrave KD, et al.: Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. J Infect Dis 1991, 163:966-970.
13. Richman D, Shih CK, Lowy I, et al.: Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 1991, 88:11241-11245.
14. Mellors JW, Dutschman GE, Im GJ, et al.: In vitro selection and molecular characterisation of human immunodeficiency virus-1 resistant to nonnucleoside inhibitors of reverse transcriptase. Mol Pharmacol 1992, 41:446-451.
15. Nunberg JH, Schleif WA, Boots EJ, et al.: Viral resistance to human immunodeficiency virus type-1-specific pyridinone reverse transcriptase inhibitors. J Virol 1991, 65:4887-4892.
16. de Jong MD, Loewenthal M, Boucher CA, et al.: Alternating nevirapine and zidovudine therapy of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity. J Infect Dis 1994, 169:1346-1350.
17. Cheeseman SH, Havlir D, McLaughlin MM, et al.: Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8:141-151.
18. Richman DD, Havlir D, Corbeil, et al.: Nevirapine resistance mutations of human immunodeficiency virus (HIV) type 1 selected during therapy. J Virol 1994, 68:1660-1666.
19. Havlir D, Cheeseman SH, McLaughlin M, et al.: High-dose nevirapine: safety, pharmacokinetics and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995, 171:537-545.
20. Richman D, Rosenthal AS, Skoog M, et al.: BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother 1991, 35:305-308.
21. Larder BA: 3′-azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodefiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992, 36:2664-2669.
22. Centers for Disease Control: Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR 1989, 38 (suppl 5):1-9.
23. Erickson DA, Mathelu E, Hattox SE, Keirns JJ: Induction of hepatic cytochrome(s) P-450 in rats by nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor. FASEB J 1993, 7:1538.
24. Donovan RM, Bush CE, Smereck SM, Baxa DM, Markowitz NP, Saravolatz LD: Rapid decrease in unintegrated human immunodeficiency virus DNA after the initiation of nucleoside therapy. J Infect Dis 1994, 170:202-205.
25. Stevenson M, Haggerty S, Lamonica CA, Meier CM, Welch S-K, Waslak AJ: Integration is not necessary for expression of human immunodeficiency virus type 1 protein products. J Virol 1990, 64:2421-2425.
26. Fischl MA: Efficacy and toxicities of combination antiretroviral therapies. 2nd International Congress on Drug Therapy of HIV Infection. Glasgow, November 1994 [abstract 7.2].